stockportfolio.pro
Kymera Therapeutics, Inc. (KYMR)
Healthcare · Biotechnology · NasdaqGM
Kymera Therapeutics, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.93M | $34.03M | $72.83M | $46.83M | $78.59M | $47.07M | $39.21M |
| Gross profit | — | — | — | $0 | $0 | $0 | $0 |
| Net income | $-41.25M | $-45.59M | $-100.22M | $-154.81M | $-146.96M | $-223.86M | $-311.35M |
| Net margin | -1405.8% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
Source: Kymera Therapeutics, Inc. SEC filings (10-K).
Explore 7 years of Kymera Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KYMR in your portfolio →
Kymera Therapeutics, Inc. financial history by metric
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. — frequently asked questions
What is Kymera Therapeutics, Inc.'s revenue?
Kymera Therapeutics, Inc. (KYMR) reported revenue of $39.21M for fiscal year 2025, down 16.7% from the prior year, according to its SEC filings.
Is Kymera Therapeutics, Inc. profitable?
No — KYMR reported a net loss of $-311.35M in fiscal 2025.
What is KYMR's P/E ratio?
Kymera Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Kymera Therapeutics, Inc. growing?
KYMR's revenue grew at roughly 2.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Kymera Therapeutics, Inc. have?
As of fiscal year 2025, KYMR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kymera Therapeutics, Inc.'s gross margin?
KYMR's gross margin was 0.0% in fiscal 2025 — gross profit of $0 on revenue of $39.21M.
What is Kymera Therapeutics, Inc.'s market cap?
Kymera Therapeutics, Inc. (KYMR) has a market capitalization of about $6.75B, based on the latest data in our nightly-refreshed cache.
When does Kymera Therapeutics, Inc.'s fiscal year end?
KYMR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Kymera Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.